112 related articles for article (PubMed ID: 22475781)
21. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
[TBL] [Abstract][Full Text] [Related]
23. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
Jacquemier J; Spyratos F; Esterni B; Mozziconacci MJ; Antoine M; Arnould L; Lizard S; Bertheau P; Lehmann-Che J; Fournier CB; Krieger S; Bibeau F; Lamy PJ; Chenard MP; Legrain M; Guinebretière JM; Loussouarn D; Macgrogan G; Hostein I; Mathieu MC; Lacroix L; Valent A; Robin YM; Revillion F; Triki ML; Seaume A; Salomon AV; de Cremoux P; Portefaix G; Xerri L; Vacher S; Bièche I; Penault-Llorca F
BMC Cancer; 2013 Jul; 13():351. PubMed ID: 23875536
[TBL] [Abstract][Full Text] [Related]
24. Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH).
Pehlivanoglu B; Serin G; Yeniay L; Zekioglu O; Gokmen E; Ozdemir N
Ann Diagn Pathol; 2017 Dec; 31():36-40. PubMed ID: 29146056
[TBL] [Abstract][Full Text] [Related]
25. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
26. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
27. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
Park IH; Kwon Y; Ro JY; Lee KS; Ro J
Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
[TBL] [Abstract][Full Text] [Related]
28. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
29. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
[TBL] [Abstract][Full Text] [Related]
31. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
32. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
33. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
34. [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma].
Long XY; Bu H; Wei B; Liu XY; Chen M; Chen J; Liu JP
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):300-3. PubMed ID: 21756822
[TBL] [Abstract][Full Text] [Related]
35. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
36. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).
Arnould L; Roger P; Macgrogan G; Chenard MP; Balaton A; Beauclair S; Penault-Llorca F
Mod Pathol; 2012 May; 25(5):675-82. PubMed ID: 22222637
[TBL] [Abstract][Full Text] [Related]
38. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
39. [Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the Reference Laboratory of Lisbon].
André S; Tomás AR; Fonseca R
Acta Med Port; 2005; 18(6):417-22. PubMed ID: 16684481
[TBL] [Abstract][Full Text] [Related]
40. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]